Discounted Cash Flow (DCF) Analysis Unlevered

89Bio Inc

89Bio Inc (ETNB)

$25.36
0.94 (+3.85%)

Operating Data

Year
A/P
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
Revenue -------
Revenue (%)
EBITDA -------
EBITDA (%)
EBIT -------
EBIT (%)
Depreciation -------
Depreciation (%)

Balance Sheet Data

Year
A/P
2018
Actual
2019
Actual
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
Total Cash -------
Total Cash (%)
Account Receivables -------
Account Receivables (%)
Inventories -------
Inventories (%)
Accounts Payable -------
Accounts Payable (%)
Capital Expenditure -------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 25.36
Beta 0.000
Diluted Shares Outstanding 13.79
Cost of Debt
Tax Rate -0.38
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 2.460
Total Debt -
Total Equity 349.69
Total Capital 349.69
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash

Year
A/P
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
Revenue -------
EBITDA -------
EBIT -------
Tax Rate -0.17%-0.38%-0.28%-0.28%-0.28%-0.28%-0.28%
EBIAT -------
Depreciation -------
Accounts Receivable -------
Inventories -------
Accounts Payable -------
Capital Expenditure -0.04-0.14-----
UFCF -------
WACC
PV UFCF -------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 2.46
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -93.33
Equity Value -
Shares Outstanding 13.79
Equity Value Per Share -